Total Payments
$899,759
2024 Payments
$390,302
Companies
31
Transactions
1,585
Medicare Patients
6,733
Medicare Billing
$338,443
Payment Breakdown by Category
Other$491,301 (54.6%)
Consulting$224,492 (25.0%)
Travel$113,675 (12.6%)
Education$37,654 (4.2%)
Food & Beverage$27,841 (3.1%)
Research$4,796 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $485,855 | 309 | 54.0% |
| Consulting Fee | $224,492 | 147 | 25.0% |
| Travel and Lodging | $113,675 | 334 | 12.6% |
| Education | $37,654 | 13 | 4.2% |
| Food and Beverage | $27,841 | 774 | 3.1% |
| Honoraria | $5,446 | 7 | 0.6% |
| Unspecified | $4,796 | 1 | 0.5% |
Payments by Type
General
$894,963
1,584 transactions
Research
$4,796
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $232,147 | 298 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $111,233 | 196 | $0 (2024) |
| Janssen Biotech, Inc. | $79,735 | 137 | $0 (2024) |
| UCB, Inc. | $68,418 | 128 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $65,145 | 66 | $0 (2024) |
| ABBVIE INC. | $64,763 | 168 | $0 (2024) |
| Lilly USA, LLC | $59,123 | 138 | $0 (2024) |
| Arcutis Biotherapeutics, Inc. | $42,424 | 66 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $26,472 | 24 | $0 (2024) |
| Dermavant Sciences, Inc. | $22,983 | 45 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $390,302 | 528 | GENZYME CORPORATION ($114,145) |
| 2023 | $283,122 | 489 | GENZYME CORPORATION ($57,676) |
| 2022 | $164,733 | 371 | GENZYME CORPORATION ($40,340) |
| 2021 | $61,602 | 197 | GENZYME CORPORATION ($19,987) |
All Payment Transactions
1,585 individual payment records from CMS Open Payments — Page 1 of 64
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $25.54 | General |
| Category: DERMATOLOGY | ||||||
| 12/26/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | Cash or cash equivalent | $392.87 | General |
| Category: Immunology | ||||||
| 12/26/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | Cash or cash equivalent | $45.91 | General |
| Category: Immunology | ||||||
| 12/24/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $444.66 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/23/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | SILIQ (Drug), DUOBRII, TARGRETIN | Food and Beverage | In-kind items and services | $11.17 | General |
| Category: Dermatology | ||||||
| 12/21/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $286.36 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/19/2024 | Eli Lilly and Company | TALTZ (Drug) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $36.66 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/17/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,920.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $787.50 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $2.58 | General |
| Category: Dermatology | ||||||
| 12/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,363.00 | General |
| Category: Immunology | ||||||
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $4,100.00 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $611.21 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $262.20 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $239.40 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $171.46 | General |
| 12/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,665.00 | General |
| Category: Immunology | ||||||
| 12/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $178.08 | General |
| Category: Immunology | ||||||
| 12/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | Cash or cash equivalent | $104.52 | General |
| Category: Immunology | ||||||
| 12/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $89.58 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $24.62 | General |
| Category: Immunology | ||||||
| 12/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | Cash or cash equivalent | $18.80 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | SILIQ (Drug), DUOBRII, TARGRETIN | Food and Beverage | In-kind items and services | $10.99 | General |
| Category: Dermatology | ||||||
| 12/10/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,269.00 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $4,796 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,716 | 3,777 | $192,882 | $93,175 |
| 2022 | 14 | 1,662 | 3,768 | $165,791 | $79,748 |
| 2021 | 16 | 1,841 | 3,960 | $195,019 | $93,733 |
| 2020 | 14 | 1,514 | 3,124 | $169,476 | $71,787 |
Total Patients
6,733
Total Services
14,629
Medicare Billing
$338,443
Procedure Codes
59
All Medicare Procedures & Services
59 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 446 | 628 | $57,318 | $30,755 | 53.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 370 | 540 | $44,309 | $17,636 | 39.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 131 | 164 | $22,071 | $11,254 | 51.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 145 | 170 | $20,704 | $9,900 | 47.8% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 291 | 1,794 | $12,561 | $6,727 | 53.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 115 | 128 | $6,915 | $3,921 | 56.7% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 23 | 34 | $6,322 | $3,497 | 55.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 61 | 61 | $8,250 | $3,373 | 40.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 27 | 31 | $4,197 | $1,727 | 41.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $3,305 | $1,305 | 39.5% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 14 | 14 | $2,143 | $1,114 | 52.0% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 30 | 35 | $2,303 | $1,075 | 46.7% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 16 | 16 | $1,492 | $605.67 | 40.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 22 | $682.88 | $191.68 | 28.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 19 | 124 | $310.00 | $93.72 | 30.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 361 | 530 | $43,507 | $17,057 | 39.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 239 | 321 | $29,272 | $15,899 | 54.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 346 | 441 | $23,813 | $12,754 | 53.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 129 | 141 | $17,332 | $8,145 | 47.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 90 | 108 | $14,535 | $7,998 | 55.0% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 296 | 1,896 | $13,432 | $7,053 | 52.5% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 23 | 32 | $6,154 | $3,084 | 50.1% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 32 | 38 | $5,144 | $2,432 | 47.3% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 49 | 49 | $4,568 | $1,768 | 38.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 21 | 21 | $2,840 | $1,358 | 47.8% |
About Douglas Diruggiero, PAC
Douglas Diruggiero, PAC is a Physician Assistant healthcare provider based in Cartersville, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1730145327.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Douglas Diruggiero, PAC has received a total of $899,759 in payments from pharmaceutical and medical device companies, with $390,302 received in 2024. These payments were reported across 1,585 transactions from 31 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($485,855).
As a Medicare-enrolled provider, Diruggiero has provided services to 6,733 Medicare beneficiaries, totaling 14,629 services with total Medicare billing of $338,443. Data is available for 4 years (2020–2023), covering 59 distinct procedure/service records.
Ad
Practice Information
- Specialty Physician Assistant
- Location Cartersville, GA
- Active Since 04/24/2006
- Last Updated 11/27/2023
- Taxonomy Code 363A00000X
- Entity Type Individual
- NPI Number 1730145327
Products in Payments
- DUPIXENT (Biological) $302,448
- TREMFYA (Drug) $85,126
- SKYRIZI (Biological) $43,012
- Sotyktu (Drug) $42,096
- Bimzelx (Biological) $28,078
- OLUMIANT (Drug) $27,830
- SPEVIGO (Drug) $25,295
- Zoryve (Drug) $25,082
- RINVOQ (Biological) $20,374
- Otezla (Drug) $18,426
- ADBRY (Biological) $12,550
- WYNZORA (Drug) $12,396
- VTAMA (Drug) $11,738
- ILUMYA (Biological) $11,393
- TAPINAROF (Drug) $11,245
- OPZELURA (Drug) $9,408
- Cimzia (Drug) $8,688
- Olumiant (Drug) $5,825
- COSENTYX (Biological) $4,498
- COSENTYX (Drug) $3,792
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Physician Assistant Doctors in Cartersville
Mrs. Abigail Matthews, Pa-C, PA-C
Physician Assistant — Payments: $8,405
Physician Assistant $8,405
Mr. William Loong, Pa-C, PA-C
Physician Assistant — Payments: $5,010
Physician Assistant $5,010
Mrs. Stacey Perry, Pa-C, PA-C
Physician Assistant — Payments: $4,476
Physician Assistant $4,476
Sarah Bell, Pa-C, PA-C
Physician Assistant — Payments: $1,604
Physician Assistant $1,604
Anthony Montes De Oca, Pa-C, PA-C
Physician Assistant — Payments: $1,445
Physician Assistant $1,445
Stephanie Hyson-Guevara, Pa, PA
Physician Assistant — Payments: $931.42
Physician Assistant $931.42